Doosan Heavy Industries & Construction (DHIC) sealed a 400 billion won order with Nepal Water & Energy Development (NWEDC) to build a 216-megawatt hydroelectric power station on the Trishuli River, 70 kilometers north of Kathmandu, over the next five years.
NWEDC, a special-purpose entity for the project, is 50 percent owned by Korea South-East Power, a South Korean electric power company, Doosan Heavy said.
According to DHIC's EPC BG head Park In-won, with opportunities to participate in domestic and foreign markets expected to increase in the future, the company will exert efforts to accelerate localization of related equipment and design and revitalize similar industries in South Korea.
He added that the order from Nepal provides momentum to the company's eco-friendly energy business, including offshore wind power and hydrogen.
Doosan Heavy will also build a 215-megawatt hydropower plant in Pakistan and has inked a memorandum of understanding with Korea South-East Power for its construction slated to start in late 2022.


Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case
OpenAI Tightens AI Safety Monitoring After Security Incidents
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
SK Hynix Shares Surge on Record $28.6 Billion Buyback
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 



